Clinical Trial

A Study to Evaluate the Safety and Tolerability of Single and Multiple Dose of STSP-0902 in Healthy Subjects

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 22, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase 1b, randomized, double-blind, placebo-controlled, single and multiple ascending dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of STSP-0902
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-05 -> 2026-07 2026-05-23
minor Completion pushed: 2026-05 -> 2026-08 2026-05-23
Trial Details
NCT Number NCT06948799
Lead Sponsor Staidson (Beijing) Biopharmaceuticals Co., Ltd
Conditions Oligozoospermia
Enrollment 64 participants
Start Date 2025-05-08
Primary Completion 2026-07 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-05-22